Donald Trump's Presidency Triggers Big Gains For Biotech Stocks

Hillary Clinton's campaign triggered dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months causing Biotech stocks to lag the S&P 500 index by over 30%. Todd Hagopian makes the case that Biotechs have the most to gain from Donald Trump's Presidency.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Hillary Clinton [+]    Nasdaq Biotechnology ETF [+]    IBB [+]    Biotech [+]    Hagopian [+]    Biotechs [+]    Donald Trump [+]   

More #news: